JP2009545309A - 組換え型生物学的製剤を製造する方法 - Google Patents
組換え型生物学的製剤を製造する方法 Download PDFInfo
- Publication number
- JP2009545309A JP2009545309A JP2009522414A JP2009522414A JP2009545309A JP 2009545309 A JP2009545309 A JP 2009545309A JP 2009522414 A JP2009522414 A JP 2009522414A JP 2009522414 A JP2009522414 A JP 2009522414A JP 2009545309 A JP2009545309 A JP 2009545309A
- Authority
- JP
- Japan
- Prior art keywords
- cell
- mirna
- mammalian
- cho
- culture
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000004519 manufacturing process Methods 0.000 title claims abstract description 37
- 108091070501 miRNA Proteins 0.000 claims abstract description 152
- 239000002679 microRNA Substances 0.000 claims abstract description 151
- 238000000034 method Methods 0.000 claims abstract description 57
- 239000003112 inhibitor Substances 0.000 claims abstract description 36
- 238000004113 cell culture Methods 0.000 claims abstract description 22
- 230000001965 increasing effect Effects 0.000 claims abstract description 17
- 239000002028 Biomass Substances 0.000 claims abstract description 12
- 210000004027 cell Anatomy 0.000 claims description 141
- 230000014509 gene expression Effects 0.000 claims description 45
- 230000012010 growth Effects 0.000 claims description 38
- 230000001939 inductive effect Effects 0.000 claims description 27
- 150000007523 nucleic acids Chemical group 0.000 claims description 18
- 239000002243 precursor Substances 0.000 claims description 18
- 108020004707 nucleic acids Proteins 0.000 claims description 13
- 102000039446 nucleic acids Human genes 0.000 claims description 13
- 210000004978 chinese hamster ovary cell Anatomy 0.000 claims description 12
- 238000001890 transfection Methods 0.000 claims description 10
- 230000022131 cell cycle Effects 0.000 claims description 8
- 108091070493 Homo sapiens miR-21 stem-loop Proteins 0.000 claims description 7
- 108091008065 MIR21 Proteins 0.000 claims description 7
- 230000003698 anagen phase Effects 0.000 claims description 6
- 230000005764 inhibitory process Effects 0.000 claims description 6
- 239000002502 liposome Substances 0.000 claims description 6
- 108091028043 Nucleic acid sequence Proteins 0.000 claims description 5
- 239000013604 expression vector Substances 0.000 claims description 5
- 239000000411 inducer Substances 0.000 claims description 5
- 238000003146 transient transfection Methods 0.000 claims description 5
- 241000699802 Cricetulus griseus Species 0.000 claims description 4
- 230000001413 cellular effect Effects 0.000 claims description 3
- 239000003795 chemical substances by application Substances 0.000 claims description 3
- 230000006698 induction Effects 0.000 claims description 3
- 210000001672 ovary Anatomy 0.000 claims description 3
- 230000002103 transcriptional effect Effects 0.000 claims description 3
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 2
- 239000001506 calcium phosphate Substances 0.000 claims description 2
- 235000011010 calcium phosphates Nutrition 0.000 claims description 2
- 238000004520 electroporation Methods 0.000 claims description 2
- 238000013518 transcription Methods 0.000 claims description 2
- 230000035897 transcription Effects 0.000 claims description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 abstract description 2
- 241001465754 Metazoa Species 0.000 abstract 1
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 16
- 238000004458 analytical method Methods 0.000 description 14
- 108091062762 miR-21 stem-loop Proteins 0.000 description 14
- 108091041631 miR-21-1 stem-loop Proteins 0.000 description 14
- 108091044442 miR-21-2 stem-loop Proteins 0.000 description 14
- 108090000623 proteins and genes Proteins 0.000 description 13
- 108091026890 Coding region Proteins 0.000 description 11
- 229960000074 biopharmaceutical Drugs 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 241000282414 Homo sapiens Species 0.000 description 6
- 238000011529 RT qPCR Methods 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 230000001404 mediated effect Effects 0.000 description 6
- 108700011259 MicroRNAs Proteins 0.000 description 5
- 230000008859 change Effects 0.000 description 5
- 238000000605 extraction Methods 0.000 description 5
- 108091092825 miR-24 stem-loop Proteins 0.000 description 5
- 108091032978 miR-24-3 stem-loop Proteins 0.000 description 5
- 108091064025 miR-24-4 stem-loop Proteins 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 102000004169 proteins and genes Human genes 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 230000006907 apoptotic process Effects 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 210000005260 human cell Anatomy 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 230000014616 translation Effects 0.000 description 4
- 102100023774 Cold-inducible RNA-binding protein Human genes 0.000 description 3
- 101710164904 Cold-inducible RNA-binding protein Proteins 0.000 description 3
- 241000699800 Cricetinae Species 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000012097 Lipofectamine 2000 Substances 0.000 description 3
- 108091030146 MiRBase Proteins 0.000 description 3
- 241000700159 Rattus Species 0.000 description 3
- 238000000692 Student's t-test Methods 0.000 description 3
- 238000009825 accumulation Methods 0.000 description 3
- 238000003491 array Methods 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 210000004962 mammalian cell Anatomy 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 238000012163 sequencing technique Methods 0.000 description 3
- 239000013598 vector Substances 0.000 description 3
- HRPVXLWXLXDGHG-UHFFFAOYSA-N Acrylamide Chemical compound NC(=O)C=C HRPVXLWXLXDGHG-UHFFFAOYSA-N 0.000 description 2
- 108091032955 Bacterial small RNA Proteins 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- 230000010190 G1 phase Effects 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 102000003886 Glycoproteins Human genes 0.000 description 2
- 108090000288 Glycoproteins Proteins 0.000 description 2
- 241000699684 Meriones unguiculatus Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 2
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 2
- 239000004098 Tetracycline Substances 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 230000000692 anti-sense effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000012472 biological sample Substances 0.000 description 2
- 230000002051 biphasic effect Effects 0.000 description 2
- 238000010367 cloning Methods 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000001502 gel electrophoresis Methods 0.000 description 2
- 230000009036 growth inhibition Effects 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 108091027963 non-coding RNA Proteins 0.000 description 2
- 102000042567 non-coding RNA Human genes 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 description 2
- 108091007428 primary miRNA Proteins 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 238000003908 quality control method Methods 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- DAEPDZWVDSPTHF-UHFFFAOYSA-M sodium pyruvate Chemical compound [Na+].CC(=O)C([O-])=O DAEPDZWVDSPTHF-UHFFFAOYSA-M 0.000 description 2
- 230000010473 stable expression Effects 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 238000012353 t test Methods 0.000 description 2
- 229960002180 tetracycline Drugs 0.000 description 2
- 229930101283 tetracycline Natural products 0.000 description 2
- 235000019364 tetracycline Nutrition 0.000 description 2
- 150000003522 tetracyclines Chemical class 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000012096 transfection reagent Substances 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- 238000010200 validation analysis Methods 0.000 description 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 108091003079 Bovine Serum Albumin Proteins 0.000 description 1
- 108091087178 Cricetulus griseus miR-21 stem-loop Proteins 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 240000008168 Ficus benjamina Species 0.000 description 1
- 244000153665 Ficus glomerata Species 0.000 description 1
- 235000012571 Ficus glomerata Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 101710124239 Poly(A) polymerase Proteins 0.000 description 1
- 108010026552 Proteome Proteins 0.000 description 1
- 102000009572 RNA Polymerase II Human genes 0.000 description 1
- 108010009460 RNA Polymerase II Proteins 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 238000013381 RNA quantification Methods 0.000 description 1
- 108091066834 Rattus norvegicus miR-21 stem-loop Proteins 0.000 description 1
- 108010034634 Repressor Proteins Proteins 0.000 description 1
- 102000009661 Repressor Proteins Human genes 0.000 description 1
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000007259 addition reaction Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 150000001412 amines Chemical group 0.000 description 1
- 230000001640 apoptogenic effect Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 239000012148 binding buffer Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- 210000004748 cultured cell Anatomy 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- KZNICNPSHKQLFF-UHFFFAOYSA-N dihydromaleimide Natural products O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 230000002900 effect on cell Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 238000013401 experimental design Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012894 fetal calf serum Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000006882 induction of apoptosis Effects 0.000 description 1
- 238000013383 initial experiment Methods 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 230000001151 other effect Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 229910052697 platinum Inorganic materials 0.000 description 1
- 229920002401 polyacrylamide Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 238000000751 protein extraction Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229940054269 sodium pyruvate Drugs 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- -1 succinimide ester Chemical class 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002123 temporal effect Effects 0.000 description 1
- 238000012085 transcriptional profiling Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000011426 transformation method Methods 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 230000010474 transient expression Effects 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000012800 visualization Methods 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/111—Antisense spanning the whole gene, or a large part of it
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Plant Pathology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Physics & Mathematics (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| IE20060587 | 2006-08-04 | ||
| PCT/IE2007/000078 WO2008015662A1 (en) | 2006-08-04 | 2007-08-03 | A method of producing recombinant biological products |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2009545309A true JP2009545309A (ja) | 2009-12-24 |
| JP2009545309A5 JP2009545309A5 (enExample) | 2010-09-16 |
Family
ID=38720408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009522414A Pending JP2009545309A (ja) | 2006-08-04 | 2007-08-03 | 組換え型生物学的製剤を製造する方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US8476244B2 (enExample) |
| EP (1) | EP2046970B2 (enExample) |
| JP (1) | JP2009545309A (enExample) |
| CN (1) | CN101541972A (enExample) |
| AU (1) | AU2007280004A1 (enExample) |
| CA (1) | CA2658301A1 (enExample) |
| WO (1) | WO2008015662A1 (enExample) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016532445A (ja) * | 2013-08-06 | 2016-10-20 | ロンザ バイオロジクス ピーエルシー | 組換えタンパク質の生産のための哺乳動物生産細胞の生成のための手段及び方法 |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2520649A3 (en) * | 2007-11-23 | 2013-02-20 | Panagene, Inc. | MicroRNA antisense PNAs, compositions comprising the same, and methods for using and evaluating the same |
| MX374424B (es) | 2012-05-21 | 2025-03-06 | Genentech Inc | Metodos para mejorar la seguridad del transporte de la barrera hematoencefalica. |
| EP3536789A1 (en) * | 2012-06-06 | 2019-09-11 | Boehringer Ingelheim International GmbH | Cell engineering using rnas |
| ES2743506T3 (es) | 2013-03-14 | 2020-02-19 | Medimmune Llc | Producción de polipéptidos recombinantes |
| WO2014204405A1 (en) * | 2013-06-18 | 2014-12-24 | Agency For Science, Technology And Research | Method for modulating recombinant protein production |
| PL3063278T3 (pl) * | 2013-11-01 | 2018-08-31 | Sementis Limited | Wytwarzanie wektora wirusowego |
| DE102017128356B4 (de) | 2017-11-30 | 2024-10-10 | TRUMPF Laser SE | Scanspiegel und Scanspiegel-Einheit für ein Laser-Scansystem |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005046156A (ja) * | 1998-06-30 | 2005-02-24 | Daewoong Pharmaceutical Co Ltd | 生体内血小板増殖効能が向上した新規なヒトトロンボポイエチン誘導体 |
| WO2005047505A2 (en) * | 2003-08-07 | 2005-05-26 | Whitehead Institute For Biomedical Research | Methods and products for expression of micro rnas |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP2530157B1 (en) * | 2003-07-31 | 2016-09-28 | Regulus Therapeutics Inc. | Oligomeric compounds and compositions for use in modulation of miRNAs |
| EP1791954A1 (en) * | 2004-09-07 | 2007-06-06 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Agents, compositions and methods for treating pathologies in which regulating an ache-associated biological pathway is beneficial |
| CA2857878A1 (en) † | 2004-11-12 | 2006-12-28 | Asuragen, Inc. | Methods and compositions involving mirna and mirna inhibitor molecules |
| WO2006133022A2 (en) † | 2005-06-03 | 2006-12-14 | The Johns Hopkins University | Compositions and methods for decreasing microrna expression for the treatment of neoplasia |
| EP2377559A1 (en) † | 2005-06-03 | 2011-10-19 | Southern Adelaide Health Service - Flinders Medical Centre | Targeting cells with altered microRNA expression |
-
2007
- 2007-08-03 CA CA002658301A patent/CA2658301A1/en not_active Abandoned
- 2007-08-03 JP JP2009522414A patent/JP2009545309A/ja active Pending
- 2007-08-03 CN CNA2007800318741A patent/CN101541972A/zh active Pending
- 2007-08-03 US US12/376,345 patent/US8476244B2/en not_active Expired - Fee Related
- 2007-08-03 EP EP07789931.8A patent/EP2046970B2/en not_active Ceased
- 2007-08-03 AU AU2007280004A patent/AU2007280004A1/en not_active Abandoned
- 2007-08-03 WO PCT/IE2007/000078 patent/WO2008015662A1/en not_active Ceased
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2005046156A (ja) * | 1998-06-30 | 2005-02-24 | Daewoong Pharmaceutical Co Ltd | 生体内血小板増殖効能が向上した新規なヒトトロンボポイエチン誘導体 |
| WO2005047505A2 (en) * | 2003-08-07 | 2005-05-26 | Whitehead Institute For Biomedical Research | Methods and products for expression of micro rnas |
Non-Patent Citations (2)
| Title |
|---|
| JPN6012043315; Ｎｕｃｌｅｉｃ Ａｃｉｄｓ Ｒｅｓ．， ２００５年， 第３３巻， １２９０-１２９７ページ * |
| JPN6012043316; Ｊ Ｂｉｏｔｅｃｈｎｏｌ．， ２００７年６月， 第１３０巻， ２１３-２１８ページ * |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2016532445A (ja) * | 2013-08-06 | 2016-10-20 | ロンザ バイオロジクス ピーエルシー | 組換えタンパク質の生産のための哺乳動物生産細胞の生成のための手段及び方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP2046970A1 (en) | 2009-04-15 |
| US20100190258A1 (en) | 2010-07-29 |
| WO2008015662A8 (en) | 2009-07-23 |
| WO2008015662A1 (en) | 2008-02-07 |
| US8476244B2 (en) | 2013-07-02 |
| EP2046970B2 (en) | 2020-04-29 |
| CA2658301A1 (en) | 2008-02-07 |
| AU2007280004A1 (en) | 2008-02-07 |
| EP2046970B1 (en) | 2014-01-08 |
| CN101541972A (zh) | 2009-09-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5735927B2 (ja) | タンパク質生産の増強のためのｍＲＮＡの一次構造の再操作 | |
| Gammell et al. | Initial identification of low temperature and culture stage induction of miRNA expression in suspension CHO-K1 cells | |
| EP2937417B1 (en) | MiRNAs enhancing cell productivity | |
| US8476244B2 (en) | Method of producing recombinant biological products | |
| WO2008029790A1 (fr) | Nouvel acide nucléique | |
| JPWO2008084319A1 (ja) | 新規核酸 | |
| CN107130024B (zh) | 一种基于依赖解旋酶DNA恒温扩增技术检测microRNA的方法 | |
| Xiao et al. | Role of microRNA-129-5p in osteoblast differentiation from bone marrow mesenchymal stem cells | |
| CN107058360A (zh) | 一种基于快速克隆技术的环状rna表达载体构建方法及其应用 | |
| US20100136547A1 (en) | Pure miRNA Sample Preparation Method | |
| CN109652529B (zh) | 骨质疏松特异性miRNA、组合物及其诊疗用途 | |
| JP2016532445A (ja) | 組換えタンパク質の生産のための哺乳動物生産細胞の生成のための手段及び方法 | |
| CN109402118B (zh) | 与蛋鸭卵泡发育相关的miRNA apla-mir-145-4及其检测引物、抑制物和应用 | |
| US9896727B2 (en) | Regulator targetting fatty acid synthase and method of using the same for improving meat quality | |
| CN103740842A (zh) | 高灵敏度小rna定量检测方法及试剂盒 | |
| WO2010103522A1 (en) | Method for detection of nucleic acid sequences | |
| CN102586237A (zh) | 一种多聚核酸分子及其应用 | |
| CN106148343B (zh) | 驴的miRNA序列、制备方法及其应用 | |
| JP2015180203A (ja) | タンパク質生産の増強のためのｍＲＮＡの一次構造の再操作 | |
| JP5572814B2 (ja) | 未分化細胞の心筋分化活性検出用マーカー、核酸分子、プライマーペア、キット、心筋分化抑制剤、未分化細胞の心筋分化活性検出方法、心筋分化活性を有する細胞の単離方法、未分化細胞の心筋分化活性のモニタリング方法、および未分化細胞の心筋分化の抑制方法 | |
| CN106148342B (zh) | 一种miRNA序列、制备方法及其应用 | |
| WO2026074556A1 (en) | Methods for rejuvenating human cells with micro rnas | |
| KR20260056818A (ko) | 소 골격근 발육 관련 circRNA 및 이의 응용 | |
| Mitchell et al. | Detection and Assessment of MicroRNA Expression in Human Disease | |
| CN119120463A (zh) | 一种具有RNA切割活性的苏糖核酶Tz2及其应用 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20100730 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20100730 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120821 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20130205 |